Determining the Optimal Dose of Tenecteplase Before Endovascular Therapy for Ischaemic Stroke (EXTEND-IA TNK Part 2)
Status:
Completed
Trial end date:
2020-02-01
Target enrollment:
Participant gender:
Summary
Patients presenting to the emergency department with acute ischemic stroke, who are eligible
for standard intravenous thrombolysis within 4.5 hours of stroke onset will be assessed for
major vessel occlusion to determine their eligibility for randomization into the trial. If
the patient gives informed consent they will be randomised 50:50 using central computerised
allocation to either 0.4mg/kg or 0.25mg/kg intravenous tenecteplase before all participants
undergo endovascular thrombectomy. The trial is prospective, randomised, open-label, blinded
endpoint (PROBE) design.
Phase:
Phase 2
Details
Lead Sponsor:
Neuroscience Trials Australia
Collaborator:
The Florey Institute of Neuroscience and Mental Health
Treatments:
Molecular Mechanisms of Pharmacological Action Plasminogen Tenecteplase Tissue Plasminogen Activator